Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Sep 26, 2014; 6(4): 371-379
Published online Sep 26, 2014. doi: 10.4252/wjsc.v6.i4.371
Published online Sep 26, 2014. doi: 10.4252/wjsc.v6.i4.371
Haploidentical vs cord blood transplantation for adults with acute myelogenous leukemia
Melhem Solh, the Blood and Marrow Transplant Group of Georgia, Northside Hospital, Atlanta, GA 30342, United States
Author contributions: Solh M solely contributed to this manuscript
Correspondence to: Melhem Solh, MD, the Blood and Marrow Transplant Group of Georgia, Northside Hospital, 5670 Peachtree Dunwoody RD NE, Atlanta, GA 30342, United States. solhx001@umn.edu
Telephone: +1-404-255-1930 Fax: +1-404-459-8510
Received: April 16, 2014
Revised: June 12, 2014
Accepted: July 17, 2014
Published online: September 26, 2014
Processing time: 162 Days and 9.6 Hours
Revised: June 12, 2014
Accepted: July 17, 2014
Published online: September 26, 2014
Processing time: 162 Days and 9.6 Hours
Core Tip
Core tip: Allogeneic hematopoeitic cell transplantation is a curative treatment for patients with acute leuekemia. Many patients lack a suitable matched donor and require another stem cell source. The choice between cord blood and mismatched relative is challenging as there is no direct comparison between the two transplantation modalities. This manuscript highlights the studies and current innovative approaches with either modality with an emphasis on the recent studies aiming at decreasing complications, enhancing engraftment and speeding immune recovery.